

Healthcare-associated infections: prospective rotational surveillance data of a training and research hospital

Pavuz Çekli, Şaban Çavuşoğlu

Department of Infectious Diseases and Clinical Microbiology, Gülhane Military Medical Academy Haydarpaşa Training Hospital, İstanbul, Turkiye

Cite this article: Çekli Y, Çavuşoğlu Ş. Healthcare-associated infections: prospective rotational surveillance data of a training and research hospital. *Ank Med J.* 2024;3(1):6-12.

| Received : | 01.01 | .2024 |
|-------------------|-------|-------|
|-------------------|-------|-------|

Accepted: 28.01.2024

Published: 31.01.2024

ABSTRACT

Aims: The monitoring and prevention of healthcare-associated infections (HAIs) are considered to be among the key measures to improve the effectiveness and quality of healthcare services. This study aimed to ascertain the prevalence of HAIs in various hospital departments and identify the causative bacterial profile, risk factors, and associations with mortality.

Methods: This prospective study included 3117 patients who were monitored in various departments of a training and research hospital. The identified HAI cases were monitored using an active, prospective, rotational surveillance method. Patient data on HAIs were recorded daily with pre-established tracking forms.

Results: The mean hospital stay of the patients was 9.9 ± 7.5 days. The HAI prevalence was 4.5% and the HAI rate was 5.5%. The HAI rate showed no difference between internal medicine and surgical departments (5.7% vs 5.5%, p>0.05), but it was higher in intensive care units (ICUs) (p<0.001). The majority of the isolated agents (65.2%) were gram-negative bacteria. Advanced age, intrinsic risk factors such as malignancy, and invasive procedures (use of central, peripheral, and urinary catheters) were associated with the development of HAIs. The frequency of HAIs was higher among deceased patients compared to survivors (25.4% vs 4.1%, p<0.001).

Conclusion: HAIs remain a major concern in hospital settings, particularly in ICUs, and they strongly correlate with intrinsic risk factors and invasive procedures. Optimized infection control measures for these risk factors can make a significant contribution to improving patient outcomes.

Keywords: Healthcare-associated infection, intensive care unit, surveillance, mortality

•

INTRODUCTION

Healthcare-associated infections (HAIs) affect hundreds of millions of patients worldwide and are among the most common causes of mortality and morbidity in hospitals.¹ Furthermore, they increase hospital costs due to additional medication use and prolonged patient hospital stays.^{2,3}

Many studies have shown that the hospital environment may be responsible for the transmission of significant nosocomial pathogens to patients.^{4,5} Bacteria isolated from hospital settings differ from those originating from the community. Troublesome bacteria such as *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and methicillin-resistant *Staphylococcus aureus* (MRSA) more frequently cause HAIs.⁶⁻⁸ Infections caused by these bacteria with high resistance rates typically require the use of broad-spectrum antibiotics, resulting in significant costs and an increase in antimicrobial resistance. The spread of resistant pathogens within and between hospitals can be mitigated with effective infection control measures. One of the most crucial components of these measures is effective surveillance methods.^{9,10} Monitoring and preventing HAI cases are considered key measures to enhance the effectiveness and quality of healthcare services. In this context, providing accurate and sufficient information about HAI cases is essential for initiating effective prevention programs in hospitals.

In this study, by implementing an active, prospective, rotational surveillance method, we aimed to determine the frequency of HAIs in our hospital's wards and ICUs, the distribution of cases across wards, the bacterial profile responsible for HAIs, risk factors in HAI cases, and the impact of HAIs on mortality.

METHODS

The study was approved by the Gülhane Military Medical Academy Haydarpaşa Training Hospital Clinical Researches Ethics Committee (Date: 08.08.2001, Decision No: 0530-63-01/264). All patients were informed about the details of the research prior to the beginning of the study. All procedures were carried out in accordance with the ethical rules and the principles of the Declaration of Helsinki.

Corresponding Author: Yavuz Çekli, yavuz.cekli@outlook.com



This prospective study was conducted at Gülhane Military Medical Academy Haydarpaşa Training Hospital Hospital between March 2002 and November 2003, utilizing an active, prospective, rotational surveillance method with the aim of monitoring hospital infections.

During the study period, a total of 3117 patients were monitored in various departments and ICUs. All cases were actively monitored using a prospective, rotational surveillance method. Cases from the department of psychiatry, dermatology, pulmonary diseases and tuberculosis, endocrinology, hematology, and oncology of our hospital were not included in the surveillance data. Cases from the departments included in the study were monitored in three phases (**Table 1**). Information pertaining to patients who developed HAIs was recorded with pre-established patient tracking forms, and all collected data were recorded daily.

Inclusion criteria for the study were as follows: patients admitted to any department or ICU of the hospital included in the study who were hospitalized for more than 48 hours and were present in the department when data collection began, and, if they had undergone any surgery, they returned within a week with signs of infection or, in the event of a foreign body/prosthesis during surgery, within a year with infection symptoms. Patients who had stayed in the department or ICU for less than 48 hours, who died or were transferred to another hospital within the first 48 hours, who showed early infection symptoms during outpatient visits or at the time of admission, whose laboratory and culture results did not support the clinical findings, or who were not suspected of HAI were not included in the study. Çekli et al.

The rates and frequencies of HAIs were calculated using the formulas below based on the criteria set by the Centers for Disease Control and Prevention (CDC) and the National Nosocomial Infection Surveillance System (NNIS):

$$Incidence = \left(\frac{Number of HAIs}{Number of hospitalized patients}\right) \times 100$$

$$Device-associated infection rate=$$

$$\left(\frac{Number of infections associated with a specific device}{Number of device days}\right) \times 1000$$

Surgical site infection data were evaluated using surgical wound classification and the American Society of Anesthesiologists (ASA) scoring system.^{11,12}

Statistical Analysis

All data were analyzed with SPSS 11.0 for Windows (SPSS Inc., Chicago, IL, USA). Numerical data determined to be normally distributed based on the results of Kolmogorov-Smirnov tests are given as mean±standard deviation, while non-normally distributed variables are given as median (minmax). For comparisons between two groups, the Student t-test and Mann-Whitney U test were used in line with the normality of the considered distribution. For comparisons between three or more groups, ANOVA and Kruskal-Wallis tests were used in line with the normality of the considered variables are given as numbers and percentages, and inter-group comparisons were conducted with chi-square and Fisher exact tests. Significance was accepted at p<0.05 (*) for all statistical analyses.

| Table 1. Services included in the study and surveillance dates | | | | | |
|--|--------------|--|-------------------|--|---|
| | | | | PERIODS | |
| | ty | Ι | | II | III |
| Services | Bed Capacity | 01-31 March 2002 01-30 April 2002 | 01-31 May 2002 | 01-31 December 2002 01-31 January 2003 01-28 February 2003 | 01-31 October 2003 01-30 November 2003 |
| Physical Therapy | 34 | Х | | Х | Х |
| General Surgery Clinic | 74 | Х | | Х | Х |
| General Surgery Intensive Care Unit | 8 | Х | | Х | Х |
| Urology | 27 | Х | | Х | Х |
| Gastroenterology | 41 | Х | | Х | Х |
| Plastic Surgery | 26 | Х | | Х | Х |
| Burn Unit | 10 | Х | | Х | Х |
| Anesthesia and Reanimation Intensive Care Unit | 10 | Х | | Х | Х |
| Orthopedics | 70 | Х | | Х | Х |
| Otorhinolaryngology | 31 | Х | | Х | Х |
| Ophthalmology | 40 | Х | | Х | Х |
| Cardiovascular Surgery Clinic | 18 | Х | | Х | Х |
| Cardiovascular Surgery Intensive Care Unit | 8 | Х | | Х | Х |
| Nephrology | 29 | Х | | Х | Х |
| Pediatrics | 26 | Х | | Х | Х |
| Neonatology | 6 | | | | |
| Cardiology Clinic | 53 | Х | | Х | Х |
| Cardiology Intensive Care Unit | 6 | Х | | Х | Х |
| Neurosurgery Clinic | 54 | | Х | Х | Х |
| Neurosurgery Intensive Care Unit | 6 | | Х | Х | Х |
| Neurology Clinic | 55 | | Х | Х | Х |
| Neurology Intensive Care Unit | 6 | | Х | Х | Х |
| Internal Medicine Clinic | 30 | | Х | Х | Х |
| Internal Medicine Intensive Care Unit | 12 | | Х | Х | Х |
| Obstetrics and Gynecology | 25 | | Х | Х | Х |
| Infectious Diseases and Clinical Microbiology | 42 | | Х | Х | Х |
| Underwater and Hyperbaric Medicine | 18 | | Х | Х | Х |
| | | | | | |

Ank Med J. 2024;3(1):6-12

Çekli et al.

RESULTS

The age range of the patients was 1-100 years (mean: 36.7 ± 23.2 years), 72% of them (n=2245) were male, and 28% (n=872) were female. The hospitalization duration was determined to range from 2 to 31 days, with a mean of 9.9±7.6 days. In the first period, 778 patients were monitored, while 1166 were monitored in the second period and 1173 in the third period. The distributions of gender, age, and hospitalization duration showed no differences between the periods (p>0.05) (Table 2).

| Table 2. Demographic characteristics of patients according to periods | | | | | | | | | |
|---|-----------------|------------|-------|-------------------------|----------------------------|--|--|--|--|
| | Ger | nder | | | Length of hospitalization, | | | | |
| Periods | Male | Female | Total | Age, years (Mean±SD) | | | | | |
| | n (%) n (%) | | | (Mean±5D) | day (Mean±SD) | | | | |
| First period | 599 (77) | 179 (23) | 778 | 33.4±22.6 | 9.6±7.6 | | | | |
| II. period | 804 (69) | 362 (31) | 1166 | 37.0±23.3 | 10.8±7.8 | | | | |
| III. period | 842 (71.8) | 331 (28.2) | 1173 | 38.6±23.1 | 9.1±6.6 | | | | |
| Total | 2245 (72) | 872 (28) | 3117 | 36.7±23.2 | 9.9±7.6 | | | | |
| Abbreviations: S | D, standard dev | | | | | | | | |

Patients were monitored in surgical and internal departments. Of the analyzed cases, 59.8% were in surgical departments, while 40.2% were in internal departments. In terms of patient density, the top three services in the surgical departments were general surgery (11.9%), orthopedics (10.9%), and urology (6.5%). In internal departments, the top three were neurology (5.7%), gastroenterology (5.3%), and physical medicine and rehabilitation (5.2%).

From among the 3117 patients monitored, 173 HAIs were identified to have occurred in 141 patients (4.5%). The HAI rate was determined to be 5.5% or 5.6 per 1000 patient

days. In internal medicine departments, these rates were respectively 5.7% or 5.4 per 1000 patient days, while in surgical departments, they were 5.5% or 5.8 per 1000 patient days (p>0.05). From the internal medicine departments, in the Underwater and Hyperbaric Medicine Service, where severe cases such as diabetic foot, osteomyelitis, and necrotizing fasciitis are monitored, the HAI rate was identified as 31.3% or 19.6 per 1000 patient days (**Table 3**).

The HAI rate in the ICUs was found to be higher compared to the general services (p<0.001). In the anesthesia ICU, the HAI rate was 180% or 117.4 cases per 1000 patient days. Meanwhile, the neurology ICU had rates of 82.3% and 44.7/1000 patient days, the neurosurgery ICU had rates of 58.8% and 39/1000 patient days, the burn unit had rates of 50% and 34.8/1000 patient days, the general surgery ICU had rates of 33.9% and 24.9/1000 patient days, and the internal medicine ICU had rates of 18.9% and 27.9/1000 patient days.

The most common cause of HAI was bloodstream infection (30.1%), followed by urinary tract infection (UTI) at 28.3%, surgical site infection (SSI) at 23.6%, skin and soft tissue infection at 11.6%, and pneumonia at 6.4%. In the first period, UTIs and SSIs were the most prevalent infections, while in the second and third periods, bloodstream infections and UTIs were most frequently observed. However, no significant difference was found between these periods (p>0.05).

The most frequently encountered intrinsic risk factors among the cases were malignancy (4.7%), diabetes mellitus (4.4%), and H2 receptor blocker usage (4.1%). Medical carerelated risk factors were predominantly peripheral catheter (41.7%), urinary catheter (8.9%), and central catheter usage (4.9%) (Table 4).

| Table 3. | Distribution of healthcare-associated infections rates by ser | vices | | | |
|------------|---|----------------------|---------------------------|-----------------|-------------------------------------|
| Section | Services | Number of inpatients | Number of HAI patients | HAI rate (%) | HAI rate (per 1000 patient days) |
| Surgical | | | | | |
| | Anesthesia Intensive Care | 15 | 27 | 180 | 117.4 |
| | Burn Unit | 17 | 10 | 58.8 | 34.9 |
| | General Surgery | 425 | 28 | 6.6 | 6.7 |
| | Plastic Surgery | 110 | 7 | 6.4 | 5.6 |
| | Neurosurgery | 190 | 10 | 5.3 | 4.7 |
| | Orthopedics | 341 | 18 | 5.3 | 4.1 |
| | Urology | 203 | 2 | 1 | 1.9 |
| | Obstetrics and Gynecology | 191 | 0 | 0 | 0 |
| | Otorhinolaryngology | 151 | 0 | 0 | 0 |
| | Ophthalmology | 134 | 0 | 0 | 0 |
| | Cardiovascular Surgery | 93 | 0 | 0 | 0 |
| | TOTAL | 1870 | 102 | 5.5 | 5.8 |
| nternal | | | | | |
| | Underwater and Hyperbaric Medicine | 32 | 10 | 31.3 | 19.6 |
| | Internal Medicine | 202 | 19 | 9.4 | 11.2 |
| | Neurology | 194 | 17 | 8.8 | 6.8 |
| | Nephrology | 116 | 8 | 6.9 | 6.1 |
| | Neonatology | 70 | 2 | 2.9 | 4.6 |
| | Cardiology | 106 | 3 | 2.8 | 2.6 |
| | Physical Medicine and Rehabilitation | 161 | 4 | 2.5 | 1.9 |
| | Pediatrics | 120 | 3 | 2.5 | 5.2 |
| | Gastroenterology | 166 | 4 | 2.4 | 1.8 |
| | Infectious Diseases and Clinical Microbiology | 80 | 1 | 1.3 | 1.4 |
| | TOTAL | 1247 | 71 | 5.7 | 5.4 |
| FOTAL | | 3117 | 173 | 5.5 | 5.6 |
| bbreviatio | ons: HAI, healthcare-associated infections. | | | | |

| | | | | Periods | |
|-------------------------|------|------|------|---------|------|
| Risk Factors | То | tal | I | II | III |
| | n | % | % | % | % |
| Intrinsic | | | | | |
| Malignancy | 145 | 4.7 | 6.2 | 3.9 | 4.4 |
| Burns | 11 | 0.4 | 0.4 | 0.7 | 0 |
| Liver failure | 17 | 0.5 | 0.4 | 0.5 | 0.7 |
| General body trauma | 0 | 0 | 0 | 0 | 0 |
| Diabetes mellitus | 137 | 4.4 | 1.7 | 4.5 | 6.1 |
| AIDS/HIV infection | 0 | 0 | 0 | 0 | 0 |
| Loss of consciousness | 19 | 0.6 | 0.4 | 0.5 | 0.9 |
| H2 receptor blocker | 127 | 4.1 | 4.1 | 3.9 | 4.2 |
| Immunosuppression | 3 | 0.1 | 0.4 | 0 | 0 |
| Transplantation | 0 | 0 | 0 | 0 | 0 |
| Respiratory failure | 21 | 0.7 | 0.5 | 0.8 | 0.7 |
| Neutropenia | 0 | 0 | 0 | 0 | 0 |
| Kidney failure | 70 | 2.2 | 2.6 | 1.7 | 2.6 |
| Transfusion | 75 | 2.4 | 2.8 | 2.3 | 2.2 |
| Medical care-related | | | | | |
| Urinary catheter | 278 | 8.9 | 8.8 | 9.1 | 9.1 |
| Peripheral catheter | 1301 | 41.7 | 53.1 | 62.6 | 61.5 |
| Central catheter | 154 | 4.9 | 5.4 | 5 | 4.6 |
| Intubation | 80 | 2.6 | 3.1 | 2.7 | 2.1 |
| Mechanical ventilation | 53 | 1.7 | 1.2 | 2.7 | 1.1 |
| Arterial cannula | 47 | 1.5 | 1.4 | 1.3 | 1.8 |
| Nasogastric tube | 109 | 3.5 | 1.9 | 4.7 | 3.3 |
| Tracheostomy | 20 | 0.6 | 0.8 | 0.8 | 0.4 |
| Peritoneal dialysis | 1 | 0.01 | 0 | 0.01 | 0 |
| Hemodialysis | 14 | 0.5 | 1.7 | 0.09 | 0 |
| Drainage catheter | 93 | 3 | 4.8 | 2.2 | 2.6 |
| Prosthesis/foreign body | 125 | 4 | 6.7 | 3.1 | 3.2 |
| Other interventions | 51 | 1.6 | 2.2 | 1.6 | 1.3 |

The incidence of HAIs in the first period was 5.8%, in the second period was 3.8%, and in the third period was 4.4% (p=0.110). The incidence of HAIs was higher among female patients compared to male patients (7.1% vs 3.5%, p<0.001). Intrinsic risk factors associated with the development of HAIs included the presence of malignancy, burns, diabetes mellitus, altered consciousness, anti-acid usage, respiratory failure, and renal failure requiring transfusion therapy (p<0.001). Additionally, it was found that other invasive procedures, excluding peritoneal dialysis (p=0.828), were also associated with the development of HAIs (p<0.001) (Table 5).

It was determined that advanced age (p<0.001), prolonged hospital stay (p<0.001), and the duration of invasive procedures (p<0.001) influenced the development of HAIs, but there was no statistically significant relationship between ASA scores and the development of HAIs (p=0.263) (Table 6).

During the study period, a causative agent was isolated in 155 of 173 HAI cases (89.5%). In 18 cases (10 SSI and 8 pneumonia) where the causative agent could not be isolated, the diagnosis of HAI was made based on clinical symptoms. The majority of the isolated agents were gram-negative bacteria (65.2%), followed by gram-positive bacteria (31%) and *Candida* species (3.8%). The most common bacterium causing HAIs was *Escherichia coli* (25.2%), followed by *staphylococci* [coagulase-negative *staphylococci* (CoNS) 16.1%, *Staphylococcus aureus* 8.4% (with 98% methicillin resistance)], *Klebsiella* spp. (14.2%), and *Pseudomonas aeruginosa* (13%) (Table 7). Cekli et al.

Regarding bloodstream infections, the most prevalent pathogens were CoNS (44.2%), followed by *Pseudomonas aeruginosa* (13.5%) and *Acinetobacter* spp. (13.5%). In cases of UTIs, *Escherichia coli* (40.7%), *Pseudomonas aeruginosa* (12.2%), and *Enterococcus* spp. (12.2%) were the primary pathogens. Among SSIs, the leading pathogens were *Escherichia coli* (35.5%), *Staphylococcus aureus* (19.4%), and *Klebsiella* spp. (16.1%) (Table 8).

During the study period, a total of 59 patients died. The HAI rate was higher among deceased patients compared to survivors (25.4% vs 4.1%, p<0.001).

| Risk factorsHAIRNNRenderMale793.0 | Table 5. Relationship betw infections and risk factors | veen the prevalen s/invasive interve | ce of healt ntions | hcare-as | sociated |
|--|---|---|-----------------------|----------|----------|
| n%rGender%793.50.001First period455.81.1Period143.80.111III. period524.40.001MalignancyYes1812.40.001BurnYes545.50.001Liver FailureYes000.368Diabetes MellitusYes947.40.001No1163.90.0011324.3Parceptor BlockerYes947.40.001Respiratory FailureYes13.330.001MunnosuppressionYes13.330.001Respiratory FailureYes1571.40.001No1304.30.0011304.30.001Respiratory FailureYes1571.40.001No1304.30.0011304.30.001Renal InsufficiencyYes1571.40.001No1304.30.0011304.30.001Peritoneal DialysisYes8731.30.001No1414.59.80.0010.001Peritoneal DialysisYes2649.10.001No1314.30.0011353.8Peritoneal DialysisYes2649.10.001No1353.80.0011363.8Peritoneal Dialysis< | Diels featore | | H | 4I | - |
| Gender Female 62 7.1 First period 45 5.8 1.1 Period 11. period 44 3.8 0.111 Malignancy Yes 18 1.2.4 0.001 Burn Yes 5 45.5 0.001 Liver Failure Yes 0 0.368 Diabetes Mellitus Yes 9 47.4 0.001 Manonsciousness Yes 9 47.4 0.001 Horonsciousness Yes 9 47.4 0.001 H2 Receptor Blocker Yes 1 33.3 0.001 Respiratory Failure Yes 1 33.3 0.001 Renal Insufficiency Yes 15 71.4 0.001 No 140 4.5 0.001 0.001 Renal Insufficiency Yes 11 15.7 0.001 No 130 4.3 0.001 0.001 Perioneal Dialysis Yes 11 <th>Risk factors</th> <th></th> <th>n</th> <th>%</th> <th>р</th> | Risk factors | | n | % | р |
| PeriodFirst period455.8II. period443.80.111III. period524.40.001AulignancyYes1812.40.001BurnYes454.50.001Liver FailureYes000.368Diabetes MellitusYes947.40.001No1163.90.0011163.9UnconsciousnessYes947.40.001No1324.30.0013.4Diabetes MellitusYes13.3.30.001MunosuppressionYes13.3.30.001Respiratory FailureYes1571.40.001No1571.40.0013.40.001Renal InsufficiencyYes1571.40.001No153.3.30.001153.01TransfusionYes1571.40.001No163.80.001163.8Peritoneal DialysisYes724.10.001No1344.30.0011344.3HumbationYes724.10.001No1344.30.0011344.3HumbationYes724.10.001No1344.30.0011344.3HumbationYes724.10.001No1344.30.001135 <t< td=""><td>Gender</td><td></td><td></td><td></td><td>0.001</td></t<> | Gender | | | | 0.001 |
| PeriodII. period443.80.111 III. period524.4MalignancyYes1812.40.001BurnYes545.50.001BurnYes000.01Itor FailureYes000.01Diabetes MellitusYes000.01Mo1414.50.0010.01Diabetes MellitusYes947.40.001MunonsciousnessYes947.40.001MunosuppressionYes103.40.001Respiratory FailureYes1571.40.001No15571.40.0010.01Renal InsufficiencyYes1571.40.001No15571.40.0010.01Renal InsufficiencyYes1571.40.001No15571.40.0011550.01Renal InsufficiencyYes73.30.001No15674.40.0011560.01No1344.30.0011653.30.001Peritoneal DialysisYes74.13.50.001No1344.5190.0011563.8No1344.30.0011563.80.001Itanay CatheterYes74.13.90.001No1344.5190.0011563.8 <tr< td=""><td></td><td></td><td></td><td></td><td></td></tr<> | | | | | |
| III.period 52 4.4 Malignancy Yes 18 12.4 0.001 Burn Yes 5 45.5 0.001 Liver Failure Yes 0 0 0.001 Diabetes Mellitus Yes 25 18.2 0.001 Diabetes Mellitus Yes 9 47.4 0.001 Muconsciousness Yes 9 47.4 0.001 H2 Receptor Blocker Yes 10 3.4 0.001 Mamunosuppression Yes 1 3.3.3 0.011 Respiratory Failure Yes 15 71.4 0.001 Read Insufficiency Yes 15 71.4 0.011 No 140 4.5 0.011 3.4 Read Insufficiency Yes 15 71.4 0.011 Read Insufficiency Yes 15 3.3.3 0.011 Read Insufficiency Yes 16 3.8 0.011 Read Insufficiency Yes 16 3.8 0.011 Read Insufficiency Yes 7 24.1 0.011 Read Insufficiency Yes 7 24.1 0.011 No 115 | Period | - | | | 0.111 |
| Malignancy No 123 4.1 0.001 Burn Yes 5 45.5 0.001 Liver Failure Yes 0 0 0.368 Diabetes Mellitus No 141 4.5 0.001 Diabetes Mellitus No 116 3.9 0.001 Unconsciousness Yes 9 47.4 0.001 H2 Receptor Blocker Yes 40 31.5 0.001 Immunosuppression Yes 1 33.3 0.001 Respiratory Failure Yes 15 71.4 0.001 Renal Insufficiency Yes 11 15.7 0.001 Renal Insufficiency Yes 87 31.3 0.001 Peritoneal Dialysis Yes 87 31.3 0.001 Peritoneal Dialysis Yes 7 24.1 0.001 Intubation Yes 7 24.1 0.001 Mo 134 4.3 0.011 0.011 | | - | 52 | 4.4 | |
| $\begin{split} & \text{No} & 123 & 4.1 & 1000 \\ & 123 & 4.1 & 1000 \\ & 136 & 4.4 & 0.001 \\ & No & 136 & 4.4 & 0.001 \\ & No & 136 & 4.4 & 0.001 \\ & 136 & 4.4 & 0.001 \\ & 136 & 4.4 & 0.001 \\ & 136 & 4.4 & 0.001 \\ & 136 & 141 & 4.5 & 0.001 \\ & No & 116 & 3.9 & 0.001 \\ & No & 132 & 4.3 & 0.001 \\ & No & 132 & 4.3 & 0.001 \\ & No & 132 & 4.3 & 0.001 \\ & No & 132 & 4.3 & 0.001 \\ & No & 132 & 4.3 & 0.001 \\ & No & 132 & 4.3 & 0.001 \\ & H2 Receptor Blocker & Yes & 40 & 31.5 & 0.001 \\ & H2 Receptor Blocker & Yes & 1 & 3.3.3 & 0.001 \\ & H2 Receptor Blocker & Yes & 15 & 71.4 & 0.001 \\ & Respiratory Failure & Yes & 15 & 71.4 & 0.001 \\ & Respiratory Failure & Yes & 15 & 71.4 & 0.001 \\ & No & 125 & 4.0 & 0.001 \\ & Renal Insufficiency & Yes & 11 & 15.7 & 0.001 \\ & Yes & 24 & 30.0 & 0.001 \\ & Yes & 24 & 1.9 & 0.001 \\ & Yes & 116 & 3.8 & 0.001 \\ & Yes & 0 & 0 & 0.828 \\ & Hemodialysis & Yes & 7 & 24.1 & 0.001 \\ & No & 141 & 4.5 & 0.001 \\ & No & 141 & 4.5 & 0.001 \\ & No & 141 & 4.5 & 0.001 \\ & No & 141 & 4.5 & 0.001 \\ & Sa & 7 & 24.1 & 0.001 \\ & No & 141 & 4.5 & 0.001 \\ & Sa & 7 & 24.1 & 0.001 \\ & No & 134 & 4.3 & 0.001 \\ & No & 115 & 3.8 & 0.001 \\ & No & 117 & 3.9 & 0.001 \\ & No & 117 & 3.9 & 0.001 \\ & No & 115 & 3.8 & 0.001 \\ & No & 115 & 3.8 & 0.001 \\ & No & 115 & 3.8 & 0.001 \\ & No & 123 & 4.0 & 0.001 \\ & No & 123 & 4.0 & 0.001 \\ & Peripheral Catheter & No & 5 & 0.3 & 0.001 \\ & Peripheral Catheter & Yes & 136 & 10.5 & 0.001 \\ & No & 121 & 4.0 & 0.001 \\ & Prosthesis & No & 121 & 4.0 & 0.001 \\ & Nasogastric Tube & No & 96 & 3.2 & 0.001 \\ & Nasogastric Tube & No & 96 & 3.2 & 0.001 \\ & Na & Sa & Sa & Sa & Sa & 0.001 \\ & Na & Sa & Sa & Sa & Sa & 0.001 \\ & Na & Sa & Sa & Sa & Sa & 0.001 \\ & Nasogastric Tube & No & 19 & 3.9 & 0.001 \\ & Na & Sa & Sa & Sa & 0.001 \\ & Na & Sa & Sa & Sa & Sa & 0.001 \\ & Na & Sa & Sa & Sa & Sa & Sa & 0.001 \\ & Na & Sa & Sa & Sa & Sa & 0.001 \\ & Na & Sa & Sa & Sa & Sa & Sa & Sa & Sa$ | | | 18 | 12.4 | 0.001 |
| Burn No 136 4.4 0.001 Liver Failure Yes 0 0 0.368 Diabetes Mellitus Yes 25 18.2 0.001 Unconsciousness No 116 3.9 0.001 Unconsciousness Yes 9 47.4 0.001 H2 Receptor Blocker Yes 40 3.5 0.001 Mmunosuppression Yes 1 3.3.3 0.001 Respiratory Failure Yes 15 71.4 0.001 Renal Insufficiency Yes 130 4.3 0.001 Renal Insufficiency Yes 130 4.3 0.001 Renal Insufficiency Yes 33.3 0.001 Renal Insufficiency Yes 31.3 0.001 Renal Insufficiency Yes 31.3 0.001 Renal Insufficiency Yes 31.3 0.001 Renal Insufficiency Yes 31.4 4.3 0.001 Intubation <td>Malignancy</td> <td>No</td> <td>123</td> <td>4.1</td> <td>0.001</td> | Malignancy | No | 123 | 4.1 | 0.001 |
| No 136 4.4 Liver Failure Yes 0 0 0.368 Diabetes Mellitus No 141 4.5 0.001 Diabetes Mellitus No 116 3.9 0.001 Unconsciousness Yes 9 47.4 0.001 H2 Receptor Blocker Yes 40 31.5 0.001 Immunosuppression Yes 1 33.3 0.001 Respiratory Failure Yes 15 71.4 0.001 Renal Insufficiency Yes 11 15.7 0.001 Transfusion Yes 25 33.3 0.001 Urinary Catheter Yes 87 31.3 0.001 No 116 3.8 0.001 0.828 Hemodialysis No 141 4.5 0.828 Intubation Yes 24 30.0 0.001 No 134 4.3 0.001 0.001 No 134 | Durr | Yes | 5 | 45.5 | 0.001 |
| Liver Failure No 141 4.5 0.368 Diabetes Mellitus Yes 25 18.2 0.001 Unconsciousness Yes 9 47.4 0.001 H2 Receptor Blocker Yes 40 31.5 0.001 Immunosuppression No 101 3.4 0.001 Respiratory Failure Yes 15 71.4 0.001 Renal Insufficiency Yes 11 15.7 0.001 Renal Insufficiency Yes 11 15.7 0.001 No 130 4.3 0.001 0.01 Renal Insufficiency Yes 11 15.7 0.001 No 130 4.3 0.001 0.01 Press 87 31.3 0.001 0.001 Urinary Catheter Yes 0 0 0.828 Hemodialysis Yes 7 24.1 0.001 No 134 4.3 0.001 0.01 Mcchanical Ventilation Yes 26 49.1 0.001 | Duill | No | 136 | 4.4 | 0.001 |
| No 141 4.5 Diabetes Mellitus Yes No 25 18.2 0.001 Unconsciousness Yes No 9 47.4 0.001 H2 Receptor Blocker Yes No 101 3.4 0.001 Immunosuppression Yes No 11 33.3 0.001 Respiratory Failure Yes No 15 71.4 0.001 Renal Insufficiency Yes No 11 15.7 0.001 Renal Insufficiency Yes No 116 3.3 0.001 Transfusion Yes No 16 3.8 0.001 Peritoneal Dialysis Yes No 116 3.8 0.001 Peritoneal Dialysis Yes No 141 4.5 0.001 Mo 141 4.5 0.001 0.828 Hemodialysis Yes No 141 4.5 0.001 No 141 4.5 0.001 0.001 Mechanical Ventilation Yes 2.6 4.0 0.001 | Liver Failure | Yes | 0 | 0 | 0 368 |
| $\begin{array}{c c c c c c } \label{eq:basic} \begin{tabulary}{ c c c } \hline Pic bick product of the term of | | No | 141 | 4.5 | 0.500 |
| No 116 3.9 Unconsciousness Yes 9 47.4 0.001 H2 Receptor Blocker Yes 40 31.5 0.001 Immunosuppression No 101 3.4 0.001 Respiratory Failure Yes 1 33.3 0.016 Respiratory Failure Yes 15 71.4 0.001 Renal Insufficiency Yes 11 15.7 0.001 Renal Insufficiency Yes 25 33.3 0.001 Transfusion Yes 25 33.3 0.001 Urinary Catheter Yes 87 31.3 0.001 Peritoneal Dialysis Yes 7 24.1 0.001 No 141 4.5 0.001 0.01 Mechanical Ventilation Yes 26 49.1 0.001 No 115 3.8 0.001 0.001 Mechanical Ventilation Yes 26 49.1 0.001 <td< td=""><td>Diabetes Mellitus</td><td>Yes</td><td>25</td><td></td><td>0.001</td></td<> | Diabetes Mellitus | Yes | 25 | | 0.001 |
| No 132 4.3 0.001 H2 Receptor Blocker Yes 40 31.5 0.001 Immunosuppression Yes 1 33.3 0.016 Respiratory Failure Yes 15 71.4 0.001 Renal Insufficiency Yes 11 15.7 0.001 Renal Insufficiency Yes 25 33.3 0.001 Transfusion Yes 25 33.3 0.001 Urinary Catheter Yes 87 31.3 0.001 Peritoneal Dialysis Yes 0 0 0.828 Hemodialysis Yes 7 24.1 0.001 Intubation Yes 7 24.1 0.001 Mo 134 4.3 0.001 0.01 Mechanical Ventilation Yes 26 49.1 0.001 No 115 3.8 90.0 0.001 Central Catheter Yes 18 90.0 0.001 <td< td=""><td>Diabetes Mellitas</td><td>No</td><td>116</td><td>3.9</td><td>0.001</td></td<> | Diabetes Mellitas | No | 116 | 3.9 | 0.001 |
| No1324.3H2 Receptor BlockerYes4031.50.001No1013.40.001ImmunosuppressionYes133.30.016Respiratory FailureYes1571.40.001Renal InsufficiencyYes1115.70.001No1254.00.001Renal InsufficiencyYes2533.30.001TransfusionYes2533.30.001Urinary CatheterYes8731.30.001No1163.80.00100.828HemodialysisYes000.828IntubationYes724.10.001No1344.30.0011344.3Mechanical VentilationYes2649.10.001No1153.890.00.001Renal CatheterYes13610.50.001No1234.0903.00.001Peripheral CatheterYes13610.50.001Peripheral CatheterYes13610.50.001No1214.00.0011214.0ProsthesisYes2016.00.001Nasogastric TubeYes2246.80.001No1214.0903.20.001Nasogastric TubeYes2246.80.001No1214.0903 | Unconsciousness | | - | | 0.001 |
| H2 Receptor Blocker No 101 3.4 0.001 Immunosuppression Yes 1 33.3 0.016 Respiratory Failure Yes 15 71.4 0.001 Renal Insufficiency Yes 11 15.7 0.001 Renal Insufficiency Yes 11 15.7 0.001 Transfusion Yes 25 33.3 0.001 Transfusion Yes 87 31.3 0.001 Urinary Catheter Yes 87 31.3 0.001 Peritoneal Dialysis Yes 0 0 0.828 Hemodialysis Yes 7 24.1 0.001 Intubation Yes 24 30.0 0.001 Mechanical Ventilation Yes 26 49.1 0.001 No 115 3.8 0.001 0.001 Respiratory Yes 18 90.0 0.001 Mechanical Ventilation No 123 4.0 0.001 Respiratory Yes 18 90.0 0.001 | | | 102 | | |
| No 101 3.4 Immunosuppression Yes 1 33.3 0.016 Respiratory Failure Yes 15 71.4 0.001 Renal Insufficiency Yes 11 15.7 0.001 Renal Insufficiency Yes 11 15.7 0.001 Transfusion Yes 25 33.3 0.001 Urinary Catheter Yes 87 31.3 0.001 Peritoneal Dialysis Yes 0 0 0.828 Hemodialysis Yes 24 0.001 No 141 4.5 0.001 Intubation Yes 24 30.0 No 134 4.3 0.001 Mechanical Ventilation Yes 26 49.1 No 115 3.8 0.001 Tracheostomy Yes 16 4.0 No 115 3.8 0.001 Peripheral Catheter Yes 26 4.0 </td <td>H2 Receptor Blocker</td> <td></td> <td></td> <td></td> <td>0.001</td> | H2 Receptor Blocker | | | | 0.001 |
| $\begin{array}{ c c c c c } \mmunosuppression & No & 140 & 4.5 & 0.016 \\ \hline No & 140 & 4.5 & 0.016 \\ \hline Respiratory Failure & Yes & 15 & 71.4 & 0.001 \\ \hline Renal Insufficiency & Yes & 11 & 15.7 & 0.001 \\ \hline Renal Insufficiency & No & 130 & 4.3 & 0.001 \\ \hline Transfusion & Yes & 25 & 33.3 & 0.001 \\ \hline Transfusion & No & 116 & 3.8 & 0.001 \\ \hline Urinary Catheter & Yes & 87 & 31.3 & 0.001 \\ \hline Peritoneal Dialysis & No & 141 & 4.5 & 0.828 \\ \hline Hemodialysis & No & 141 & 4.5 & 0.001 \\ \hline Renal Insufficiency & Yes & 7 & 24.1 & 0.001 \\ \hline No & 134 & 4.3 & 0.001 \\ \hline Rendialysis & Yes & 7 & 24.1 & 0.001 \\ \hline Rendialysis & Yes & 7 & 24.1 & 0.001 \\ \hline Rechanical Ventilation & Yes & 26 & 49.1 & 0.001 \\ \hline Rechanical Ventilation & Yes & 26 & 49.1 & 0.001 \\ \hline Rechanical Ventilation & Yes & 18 & 90.0 & 0.001 \\ \hline Rechanical Catheter & Yes & 136 & 10.5 & 0.001 \\ \hline Rechanical Catheter & Yes & 136 & 10.5 & 0.001 \\ \hline Reripheral Catheter & Yes & 136 & 10.5 & 0.001 \\ \hline Prosthesis & No & 121 & 4.0 & 0.001 \\ \hline Prosthesis & Yes & 20 & 21.5 & 0.001 \\ \hline No & 121 & 4.0 & 0.001 \\ \hline No & 121$ | 1 | | | | |
| No 140 4.5 Respiratory Failure Yes 15 71.4 0.001 Renal Insufficiency Yes 11 15.7 0.001 Renal Insufficiency Yes 25 33.3 0.001 Transfusion Yes 25 33.3 0.001 Urinary Catheter Yes 87 31.3 0.001 Peritoneal Dialysis Yes 0 0 34 4.3 Hemodialysis Yes 7 24.1 0.001 Intubation Yes 24 30.0 0.001 Mo 134 4.3 0.001 Mechanical Ventilation Yes 26 49.1 0.001 No 134 4.3 0.001 3.8 Tracheostomy Yes 16 3.8 0.001 Peripheral Catheter Yes 18 90.0 0.001 No 123 4.0 0.001 0.001 Peripheral Catheter Yes 136 10.5 0.001 No 123 4.0 | Immunosuppression | | - | | 0.016 |
| Respiratory Failure No 125 4.0 0.001 Renal Insufficiency Yes 11 15.7 0.001 No 130 4.3 0.001 Transfusion Yes 25 33.3 0.001 Urinary Catheter Yes 87 31.3 0.001 Peritoneal Dialysis Yes 0 0 0.828 Hemodialysis Yes 7 24.1 0.001 Intubation Yes 7 24.1 0.001 Mo 134 4.3 0.001 0.01 Mechanical Ventilation Yes 24 30.0 0.001 No 117 3.9 0.001 0.001 Mechanical Ventilation Yes 26 49.1 0.001 No 115 3.8 0.001 0.001 Central Catheter Yes 18 90.0 0.001 No 123 4.0 0.001 0.001 Peripheral Catheter <td>11</td> <td></td> <td></td> <td></td> <td></td> | 11 | | | | |
| Renal Insufficiency Yes 11 15.7 0.001 Transfusion Yes 25 33.3 0.001 Transfusion Yes 87 31.3 0.001 Urinary Catheter Yes 87 31.3 0.001 Peritoneal Dialysis Yes 0 0 0.828 Hemodialysis Yes 7 24.1 0.001 No 134 4.3 0.001 Intubation Yes 7 24.1 0.001 No 134 4.3 0.001 0.01 Mechanical Ventilation Yes 26 49.1 0.001 No 117 3.9 0.001 0.01 Mechanical Ventilation Yes 26 49.1 0.001 No 115 3.8 0.001 0.001 Central Catheter Yes 18 90.0 0.001 No 123 4.0 0.001 0.001 Peripheral Catheter Yes 136 10.5 0.001 No 5 0. | Respiratory Failure | | | | 0.001 |
| Renal Insufficiency No 130 4.3 0.001 Transfusion Yes 25 33.3 0.001 Iransfusion Yes 87 31.3 0.001 Urinary Catheter Yes 87 31.3 0.001 Peritoneal Dialysis Yes 0 0 0.828 Hemodialysis Yes 7 24.1 0.001 Intubation Yes 26 49.1 0.001 Mechanical Ventilation Yes 26 49.1 0.001 Mechanical Ventilation Yes 26 49.1 0.001 Mechanical Ventilation Yes 18 90.0 0.001 Tracheostomy Yes 18 90.0 0.001 Remainage Catheter Yes 136 10.5 0.001 No 123 4.0 0.001 100 Peripheral Catheter Yes 136 10.5 0.001 No 5 0.3 0.001 0.001< | 1 / | | | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | Renal Insufficiency | | | | 0.001 |
| Transfusion No 116 3.8 0.001 Winary Catheter Yes 87 31.3 0.001 Peritoneal Dialysis Yes 0 0 0.828 Hemodialysis Yes 7 24.1 0.001 Hemodialysis Yes 7 24.1 0.001 Intubation Yes 24 30.0 0.001 Mechanical Ventilation Yes 26 49.1 0.001 Mechanical Ventilation Yes 26 49.1 0.001 Mechanical Ventilation Yes 18 90.0 0.001 Mechanical Ventilation No 115 3.8 0.001 Mechanical Ventilation Yes 18 90.0 0.001 Central Catheter Yes 136 10.5 0.001 Peripheral Catheter Yes 136 10.5 0.001 No 5 0.3 0.001 0.001 Prosthesis Yes 20 16.0 0.001 No 96 3.2 0.001 0.001 | | | | | |
| Urinary Catheter Yes No 87 31.3 (19) $\partial \partial $ | Transfusion | | | | 0.001 |
| Urinary Catheter No 54 1.9 0.001 Peritoneal Dialysis Yes 0 0 0.828 Hemodialysis Yes 7 24.1 0.001 Hemodialysis Yes 7 24.1 0.001 Intubation Yes 24 30.0 0.001 Mechanical Ventilation Yes 26 49.1 0.001 Mechanical Ventilation Yes 26 49.1 0.001 Mechanical Ventilation No 115 3.8 0.001 Tracheostomy Yes 18 90.0 0.001 Tracheostomy Yes 51 33.1 0.001 Peripheral Catheter Yes 136 10.5 0.001 Peripheral Catheter Yes 136 10.5 0.001 No 5 0.3 0.001 115 0.001 Peripheral Catheter Yes 136 10.5 0.001 No 5 0.3 0.001 0.001 Prosthesis No 121 4.0 0.00 | | | | | |
| $\begin{array}{c c c c c c } Peritoneal Dialysis & Yes & 0 & 0 & \\ No & 141 & 4.5 & \\ No & 141 & 4.5 & \\ Peritoneal Dialysis & Yes & 7 & 24.1 & \\ No & 134 & 4.3 & \\ No & 134 & 4.3 & \\ No & 134 & 4.3 & \\ No & 117 & 3.9 & \\ No & 117 & 3.9 & \\ No & 117 & 3.9 & \\ Peritoneal Ventilation & Yes & 26 & 49.1 & \\ No & 115 & 3.8 & \\ Peritoneal Catheter & Yes & 18 & 90.0 & \\ No & 123 & 4.0 & \\ No & 123 & 4.0 & \\ No & 123 & 4.0 & \\ No & 90 & 3.0 & \\ Peripheral Catheter & Yes & 136 & 10.5 & \\ No & 90 & 3.0 & \\ Prosthesis & No & 5 & 0.3 & \\ Prosthesis & Yes & 20 & 21.5 & \\ No & 121 & 4.0 & \\ No & 121 & 121 & \\ No & 121 &$ | Urinary Catheter | | | | 0.001 |
| Peritoneal Dialysis No 141 4.5 0.828 Hemodialysis Yes 7 24.1 0.001 Intubation Yes 24 30.0 0.001 Intubation Yes 24 30.0 0.001 Mechanical Ventilation Yes 26 49.1 0.001 Mechanical Ventilation Yes 26 49.1 0.001 Tracheostomy Yes 18 90.0 0.001 Tracheostomy Yes 18 90.0 0.001 Central Catheter Yes 51 33.1 0.001 Peripheral Catheter Yes 136 10.5 0.001 Drainage Catheter Yes 20 21.5 0.001 Prosthesis Yes 20 16.0 0.001 No 121 4.0 0.001 114 No 121 4.0 0.001 114 No 121 4.0 0.001 114 115 | | | | | |
| HemodialysisYes No7 24.1 13424.1 4.30.001IntubationYes No24 1173.9 3.90.001Mechanical VentilationYes No26 11549.1 3.8 3.0010.001TracheostomyYes No125 10013.8 3.11 0.0010.001Central CatheterYes No51 133.1 0.0013.001Peripheral CatheterYes No136 5 0.30.001Drainage CatheterYes No20 12121.5 0.001ProsthesisYes No20 12116.00 0.001Nasogastric TubeYes No45 96 3.20.001Arterial CannulaYes No22 No46.8 0.001 | Peritoneal Dialysis | | | | 0.828 |
| Hemodialysis No 134 4.3 0.001 Intubation Yes 24 30.0 0.001 No 117 3.9 0.001 Mechanical Ventilation Yes 26 49.1 0.001 Mechanical Ventilation Yes 26 49.1 0.001 Tracheostomy Yes 18 90.0 0.001 Tracheostomy No 123 4.0 0.001 Central Catheter Yes 51 33.1 0.001 Peripheral Catheter Yes 136 10.5 0.001 Drainage Catheter Yes 20 21.5 0.001 Prosthesis No 121 4.0 0.001 Nasogastric Tube Yes 20 16.0 0.001 No 121 4.0 0.001 0.001 Nasogastric Tube Yes 45 41.3 0.001 No 96 3.2 0.001 0.001 0.001 <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | Hemodialysis | | | | 0.001 |
| $\begin{array}{c c c c c c c c } & No & 117 & 3.9 & 0.001 \\ \hline No & 117 & 3.9 & 0.001 \\ \hline Mechanical Ventilation & No & 115 & 3.8 & 0.001 \\ \hline No & 115 & 3.8 & 90.0 & 0.001 \\ \hline Tracheostomy & Yes & 18 & 90.0 & 0.001 \\ \hline Central Catheter & Yes & 51 & 33.1 & 0.001 \\ \hline Central Catheter & Yes & 136 & 10.5 & 0.001 \\ \hline Peripheral Catheter & Yes & 136 & 10.5 & 0.001 \\ \hline Drainage Catheter & Yes & 20 & 21.5 & 0.001 \\ \hline Drainage Catheter & Yes & 20 & 16.0 & 0.001 \\ \hline Prosthesis & No & 121 & 4.0 & 0.001 \\ \hline Nasogastric Tube & Yes & 45 & 41.3 & 0.001 \\ \hline Nasogastric Tube & Yes & 22 & 46.8 & 0.001 \\ \hline Arterial Cannula & Yes & 22 & 46.8 & 0.001 \\ \hline \end{array}$ | | | | | |
| $\begin{array}{c c c c c c c } & Yes & 26 & 49.1 \\ & No & 115 & 3.8 & & \\ 115 & 3.8 & & 90.0 & \\ & 115 & 3.8 & & 90.0 & \\ & 115 & 3.8 & & 90.0 & & \\ & Persecond Prosthesis & & & & & & & \\ & Yes & 136 & 10.5 & & & & & & & & \\ & No & & & & & & & & & & & & & & & \\ & No & & & & & & & & & & & & & & & & \\ & Prosthesis & & & & & & & & & & & & & & & & & & $ | Intubation | | | | 0.001 |
| No115 3.8 TracheostomyYes1890.0No123 4.0 0.001 Central CatheterYes 51 33.1 No90 3.0 0.001 Peripheral CatheterYes 136 10.5 No 5 0.3 0.001 Drainage CatheterYes 20 21.5 No121 4.0 0.001 ProsthesisYes 20 16.0 Nasogastric TubeYes 45 41.3 No96 3.2 0.001 Arterial CannulaYes 22 46.8 No119 3.9 0.001 | | | | | |
| $\begin{array}{c c c c c c c } & Yes & 18 & 90.0 \\ & No & 123 & 4.0 \\ \hline No & 123 & 4.0 \\ \hline Peripheral Catheter & Yes & 51 & 33.1 \\ & No & 90 & 3.0 \\ \hline Peripheral Catheter & Yes & 136 & 10.5 \\ & No & 5 & 0.3 \\ \hline Drainage Catheter & Yes & 20 & 21.5 \\ & No & 121 & 4.0 \\ \hline Prosthesis & Yes & 20 & 16.0 \\ & No & 121 & 4.0 \\ \hline No & 96 & 3.2 \\ \hline Arterial Cannula & Yes & 22 & 46.8 \\ & No & 119 & 3.9 \\ \hline \end{array}$ | Mechanical Ventilation | No | 115 | 3.8 | 0.001 |
| No1234.0Central CatheterYes5133.1No903.0 0.001 Peripheral CatheterYes13610.5No50.3 0.001 Drainage CatheterYes2021.5No1214.0 0.001 ProsthesisYes2016.0No1214.0 0.001 Nasogastric TubeYes4541.3No963.2 0.001 Arterial CannulaYes2246.8No1193.9 0.001 | | | 18 | 90.0 | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Tracheostomy | No | 123 | 4.0 | 0.001 |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | | Yes | 51 | 33.1 | 0.001 |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Central Catheter | No | 90 | 3.0 | 0.001 |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | Devial cut Cuthatan | Yes | 136 | 10.5 | 0.001 |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | Peripheral Catheter | No | 5 | 0.3 | 0.001 |
| No 121 4.0 Prosthesis Yes 20 16.0 No 121 4.0 0.001 Nasogastric Tube Yes 45 41.3 No 96 3.2 0.001 Arterial Cannula Yes 22 46.8 No 119 3.9 0.001 | Drainage Cathotor | Yes | 20 | 21.5 | 0.001 |
| Prosthesis No 121 4.0 0.001 Nasogastric Tube Yes 45 41.3 0.001 No 96 3.2 0.001 Arterial Cannula Yes 22 46.8 No 119 3.9 0.001 | Dramage Catheter | No | 121 | 4.0 | 0.001 |
| $\begin{array}{c ccc} No & 121 & 4.0 \\ \hline Na sogastric Tube & Yes & 45 & 41.3 \\ No & 96 & 3.2 \\ \hline Arterial Cannula & Yes & 22 & 46.8 \\ \hline No & 119 & 3.9 \\ \hline \end{array} \begin{array}{c} 0.001 \\$ | Prosthesis | Yes | 20 | 16.0 | 0.001 |
| Nasogastric TubeNo963.20.001Arterial CannulaYes2246.80.001No1193.90.001 | 1 103010313 | No | 121 | 4.0 | 0.001 |
| No 96 3.2 Arterial Cannula Yes 22 46.8 No 119 3.9 0.001 | Nasogastric Tube | Yes | 45 | 41.3 | 0.001 |
| Arterial Cannula 0.001 No 119 3.9 | - avoguette tube | No | 96 | 3.2 | 0.001 |
| No 119 3.9 | Arterial Cannula | | | | 0.001 |
| | | | 119 | 3.9 | |

Table 6. Relationship of healthcare-associated infections development with age, hospitalization duration, ASA score, and duration of invasive procedures

| Variables | HAI | n (%) | Mean±SD | р | |
|-------------------------|-----|-------------|----------------|-------|--|
| A | Yes | 141 (4.5) | 54.9±24.5 | 0.001 | |
| Age, years | No | 2976 (95.5) | 35.8±22.7 | 0.001 | |
| Longth of stay, day | Yes | 141 (4.5) | 18.9 ± 8.7 | 0.001 | |
| Length of stay, day | No | 2976 (95.5) | 9.4±7.2 | 0.001 | |
| ASA score | Yes | 44 (4.6) | 2.1±0.5 | 0.263 | |
| ASA SCOLE | No | 908 (95.4) | 2.0 ± 0.1 | 0.265 | |
| Duration of urinary | Yes | 87 (31.2) | 17.1±9.2 | 0.001 | |
| catheter, day | No | 191 (68.8) | 8.1±7.3 | 0.001 | |
| Duration of intubation, | Yes | 24 (30) | 12.1±9.4 | 0.001 | |
| day | No | 56 (70) | 2.8±3.5 | 0.001 | |
| Duration of central | Yes | 51 (33.1) | 14.6±8.9 | 0.001 | |
| catheter, day | No | 103 (66.9) | 5.7±5.4 | 0.001 | |
| Duration of peripheral | Yes | 138 (10.6) | 18.4±8.7 | 0.001 | |
| catheter, day | No | 1163 (89.4) | 6.4±5.6 | 0.001 | |

Abbreviations: HAI, healthcare-associated infections; SD, standard deviation

Table 7. Distribution of healthcare-associated infections agents by periods

| | Periods | | | | | | Total | | | |
|----------------------------------|---------|------------|----------|-----------|--------|-----------|-----------|--------|--|--|
| HAI agents | Ι | | | II | | III | | Total | | |
| | n | % | n | % | n | % | n | % | | |
| Gram (+) bacteria | 11 | 26.8 | 20 | 37.1 | 17 | 28.3 | 48 | 31.0 | | |
| CoNS | 3 | 7.3 | 11 | 20.4 | 11 | 18.3 | 25 | 16.1 | | |
| Staphylococcus aureus | 5 | 12.2 | 5 | 9.3 | 3 | 5.0 | 13 | 8.4 | | |
| Enterococcus spp. | 3 | 7.3 | 4 | 7.4 | 3 | 5.0 | 10 | 6.5 | | |
| Gram (-) bacteria | 29 | 70.7 | 31 | 57.4 | 41 | 68.3 | 101 | 65.2 | | |
| Escherichia coli | 8 | 19.5 | 14 | 26.0 | 17 | 28.3 | 39 | 25.2 | | |
| Klebsiella spp. | 11 | 26.9 | 4 | 7.4 | 7 | 11.7 | 22 | 14.2 | | |
| Pseudomonas aeruginosa | 4 | 9.6 | 8 | 14.8 | 8 | 13.3 | 20 | 13.0 | | |
| Acinetobacter spp. | 2 | 4.9 | 2 | 3.7 | 6 | 10.0 | 10 | 6.5 | | |
| Proteus spp. | 2 | 4.9 | 3 | 5.5 | 3 | 5.1 | 8 | 5.1 | | |
| Enterobacter spp. | 2 | 4.9 | 0 | 0 | 0 | 0 | 2 | 1.3 | | |
| Candida spp. | 1 | 2.5 | 3 | 5.5 | 2 | 3.4 | 6 | 3.8 | | |
| Total | 41 | 100 | 54 | 100 | 60 | 100 | 155 | 100 | | |
| Abbreviations: CoNs, Coagulase-n | egativ | e staphylo | cocci; I | IAI, heal | thcare | associate | ed infect | tions; | | |

DISCUSSION

In Turkiye, the HAI rate is generally reported to be between 1% and 16.5%, and in ICUs, it ranges from 5.3% to 65.3%.¹³⁻¹⁶ Based on these studies, the HAI rate in our research (5.5%) is comparatively low. This variation could be attributed to differences in hospital bed capacities, the types of patients, distinct risk factors, and the non-inclusion of certain departments where HAIs are more prevalent, such as hematology, oncology, and transplantation, in our study. Çekli et al.

In our study, the HAI rates identified in the ICUs, ranging from 18.9% to 180%, were higher compared to those of general services. In the period in which our study was conducted, HAI rates in the reanimation units of university hospitals in our country were reported to range broadly between 5.3% and 171.8%.^{17,18} The HAI rate of 180% obtained for the resuscitation unit in our study was slightly higher than the upper limit of the studies mentioned above. The reason for this might be that our hospital's resuscitation department admits patients with severely deteriorated general conditions due to ease of patient care. Compared to other departments, patients might stay longer in this unit and experience multiple HAI episodes. Additionally, the combination of fewer patients staying for extended periods and experiencing multiple HAI events diminishes the denominator in incidence calculations, resulting in an elevated rate.

The types of HAIs observed in ICUs vary according to the type and capacity of the particular ICU. In our study, bloodstream infections were the most common cause. This was followed by UTIs, SSIs, skin and soft tissue infections, and pneumonia, respectively. In studies conducted in ICUs during the same period in different countries, similar HAI rates were found, excluding the rates for pneumonia.^{18,19} The low rate of hospital-acquired pneumonia in our study might be due to reduced utilization of equipment such as ventilators that heightens infection risk and the complexities of diagnosis during the period in question. However, in a recent study, it was reported that 83.7% of HAIs were lower respiratory tract infections, while only 2.9% were bloodstream infections.²⁰ It was also reported that the preventive and control measures taken in response to the COVID-19 pandemic reduced the rate of nosocomial infections in almost all departments excluding ICUs, and particularly respiratory, gastrointestinal, and oral infections. However, no difference was observed in rates of bloodstream infections and catheter-related infections before and after the COVID-19 pandemic.6

Ventilators, endotracheal tubes, catheters, and surgical wounds are identified as the most common risk factors contributing to the development of HAIs.^{8,21} Furthermore, there is a positive correlation between the type of procedure and the resulting HAI. In ICUs where urinary catheter usage is high, UTIs are more frequent. Likewise, when central or peripheral catheter usage is involved, catheter infections or bloodstream infections are commonly observed. Invasive procedures, excluding peritoneal dialysis, were found to be associated with the development of HAIs. In cases where HAIs developed, the durations of intubation and central catheter, urinary catheter, and peripheral catheter usage were longer compared to cases without HAIs, and, in parallel, there was an elevated risk of HAIs.^{21,22}

| Table 8. Distribution of isolated agents according to the type of healthcare-associated infections | | | | | | | | | | |
|--|-------------|--------------|-------------|---------------|--------------------------|------|-----------------|-----|-----------|------|
| A | Bloodstream | n Infections | Urinary Tra | ct Infections | Surgical Site Infections | | Skin Infections | | Pneumonia | |
| Agents | n | % | n | % | n | % | n | % | n | % |
| Klebsiella spp. | 6 | 11.5 | 5 | 10.2 | 5 | 16.1 | 6 | 30 | 0 | 0 |
| Escherichia coli | 3 | 5.8 | 20 | 40.7 | 11 | 35.5 | 5 | 25 | 0 | 0 |
| Pseudomonas aeruginosa | 7 | 13.5 | 6 | 12.2 | 2 | 6.5 | 4 | 20 | 1 | 33.3 |
| Staphylococcus aureus | 3 | 5.8 | 1 | 2.1 | 6 | 19.4 | 2 | 10 | 1 | 33.3 |
| CoNS | 23 | 44.2 | 0 | 0 | 2 | 6.5 | 0 | 0 | 0 | 0 |
| Acinetobacter spp. | 7 | 13.5 | 2 | 4.1 | 0 | 0 | 0 | 0 | 1 | 33.3 |
| Enterobacter spp. | 0 | 0 | 1 | 2.1 | 1 | 3.2 | 0 | 0 | 0 | 0 |
| Candida spp. | 1 | 1.9 | 5 | 10.2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Enterococcus spp | 1 | 1.9 | 6 | 12.2 | 2 | 6.5 | 1 | 5 | 0 | 0 |
| Proteus spp. | 1 | 1.9 | 3 | 6.1 | 2 | 6.5 | 2 | 10 | 0 | 0 |
| Total | 52 | 100 | 49 | 100 | 31 | 100 | 20 | 100 | 3 | 100 |
| A hhan intiger of CaNie and subset a | | | | | | | | | | |

🛛 Çekli et al. 🗖

Bacteria isolated from hospital environments differ from those originating from the community, and specific problematic bacteria are the primary causes of HAIs.^{23,24} The isolated agents vary according to the types of HAIs. In previous studies, it was reported that the most frequently isolated agents in cases of catheter-related bloodstream infection were CoNS and Staphylococcus aureus, while in cases of UTIs, the agents were Escherichia coli, other gram-negative bacteria, Pseudomonas aeruginosa, and CoNS. In cases of ventilator-associated pneumonia, the reported agents were Pseudomonas aeruginosa, Acinetobacter spp., and other gram-negative bacteria. In cases of burn-related infections, Staphylococcus aureus is typically identified as the causative agent in the initial 7 days, whereas in later stages, Pseudomonas aeruginosa and other gram-negative bacteria are found to be responsible.^{6-8,18-20} In our study, we found that CoNS were the predominant agents in bloodstream infections, while Escherichia coli was responsible for UTIs and SSIs.

In addition to negative impacts such as prolonged hospitalization and economic losses, the most significant consequence of HAIs is a high rate of mortality. Among cases that ended in death, the HAI prevalence was greater than that observed among survivors. The general health of the patient, comorbidities, duration of ICU stay, surgeries undertaken, invasive methods, the nature of the infection, and the causative agent's type and sensitivity to antibiotics are all risk factors directly influencing the prognosis.¹²

CONCLUSION

In hospitals, HAIs are among the significant causes of increased morbidity and mortality. Although their development might be viewed as inevitable, various strategies can be implemented to mitigate this risk, including conducting active surveillance in hospitals, emphasizing education, promoting hand hygiene habits, strictly adhering to asepsis and antisepsis rules, avoiding unnecessary diagnostic and therapeutic interventional procedures, monitoring invasive interventions closely, preventing the colonization of pathogenic bacteria, regulating antibiotic use in the hospital to maintain low levels of microbial resistance, and using broad-spectrum antibiotics only for treatment purposes rather than prophylactically. The implementation of these controls and precautions can be beneficial in preventing and reducing HAIs.

ETHICAL DECLARATIONS

Ethics Committee Approval

The study was performed in accordance with the Declaration of Helsinki and was approved by the Gülhane Military Medical Academy Haydarpaşa Training Hospital Ethics Committee (Date: 08.08.2001, Decision No: 0530-63-01/264).

Informed Consent

The need for informed consent was waived with the approval of the Gülhane Military Medical Academy Haydarpaşa Training Hospital Ethics Committee due to the study's retrospective design.

Referee Evaluation Process

Externally peer-reviewed.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Financial Disclosure

The authors declared that this study has received no financial support.

Author Contributions

All of the authors declare that they have all participated in the design, execution, and analysis of the paper, and that they have approved the final version.

REFERENCES

- Ulusal sağlık hizmeti ilişkili enfeksiyonlar sürveyans rehberi (2017). TC Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğ, Ankara. 2019:1-60.
- 2. Burke JP. Infection control a problem for patient safety. *N Engl J Med.* 2003;348(7):651-656.
- 3. Askarian M, Gooran NR. National nosocomial infection surveillance system-based study in Iran: additional hospital stay attributable to nosocomial infections. *Am J Infect Control.* 2003;31(8):465-468.
- 4. Facciola A, Pellicano GF, Visalli G, et al. The role of the hospital environment in the healthcare-associated infections: a general review of the literature. *Eur Rev Med Pharmacol Sci.* 2019;23(3):1266-1278.
- Voidazan S, Albu S, Toth R, Grigorescu B, Rachita A, Moldovan I. Healthcare associated infections-a new pathology in medical practice? *Int J Environ Res Public Health.* 2020;17(3):760.
- 6. Su C, Zhang Z, Zhao X, et al. Changes in prevalence of nosocomial infection pre- and post-COVID-19 pandemic from a tertiary hospital in China. *BMC Infect Dis.* 2021;21(1):693.
- Lemiech-Mirowska E, Kiersnowska ZM, Michalkiewicz M, Depta A, Marczak M. Nosocomial infections as one of the most important problems of healthcare system. *Ann Agric Environ Med.* 2021;28(3):361-366.
- Pezhman B, Fatemeh R, Amir R, Mahboobeh R, Mohammad F. Nosocomial infections in an Iranian educational hospital: an evaluation study of the Iranian nosocomial infection surveillance system. *BMC Infect Dis.* 2021;21(1):1256.
- 9. Storr J, Twyman A, Zingg W, et al. Core components for effective infection prevention and control programmes: new WHO evidence-based recommendations. *Antimicrob Resist Infect Control.* 2017;6(1):6.
- Struelens MJ. The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions. *BMJ*. 1998;317(7159):652-654.
- 11. Smyth E, Emmerson A. Surgical site infection surveillance. J Hospital Infect. 2000;45(3):173-184.
- Gaynes RP, Culver DH, Horan TC, Edwards JR, Richards C, Tolson JS. Surgical site infection (SSI) rates in the United States, 1992–1998: the national nosocomial infections surveillance system basic SSI risk index. *Clin Infect Dis.* 2001;33(Supplement_2):69-77.
- 13. Sönmez A, Öztürk ŞB, Abacigil F. Sağlık hizmeti ilişkili enfeksiyon epidemiyolojisi ve sürveyansı. *Hemşirelik Bilimi Derg.* 2021;4(1):41-45.
- Erdem HA, Sipahi OR, Kepeli N, et al. Ege Üniversitesi Hastanesi'nde hastane infeksiyonları nokta prevalansı. Mediterranean J Infect Microbes Antimicrobials. 2015;4:12.
- Buke C, Sipahi O, Tasbakan M, et al. İç hastalıkları yoğun bakımda gelişen enfeksiyonların değerlendirilmesi. *Enfeksiyon Derg.* 2005;19(1): 67-73.
- 16. Görenek L, Beşirbellioğlu B, Gül C, Tabak F, Hacıbektaşoğlu A. GATA Eğitim Hastanesi'nde hastane infeksiyonu insidansı. Hastane İnfeksiyonları Derg. 1997;1:97-100.
- Arslan H, Gürdoğan K. Yoğun bakım ünitelerinde gözlenen hastane infeksiyonları. Hastane İnfeksiyonları Derg. 1999;3:165-170.
- Erol S, Kürflat H, Özkurt Z, Parlak M, Taflyaran M. Reanimasyon ünitemizdeki hastane infeksiyonlari. *Hastane İnfeksiyonları Derg.* 2000;4:97-100.
- Saltoğlu N, Öztürk C, Taşova Y, İncecik Ş, Paydaş S, Dündar İH. Yoğun bakım ünitelerinde infeksiyon nedeniyle izlenen hastalarda etkenler, risk faktörleri, antibiyotik direnci ve prognozun değerlendirilmesi. *Flora.* 2000;5(4):229-237.
- Alanlı R, Beşirbellioğlu BA. Erişkin yoğun bakım ünitesindeki hastane enfeksiyonu etkenlerinin değerlendirilmesi: retrospektif çalışma. Akdeniz Tıp Derg. 2023;9(1):37-43.
- Karami G, Khazei M, Rasuli Ravandi F, Emtiyazipoor Z. Evaluating the effect of hospital medical instruments on the nosocomial infection risk. *Nursing Midwifery J.* 2015;13(7):579-587.

- Hugonnet S, Sax H, Eggimann P, Chevrolet JC, Pittet D. Nosocomial bloodstream infection and clinical sepsis. *Emerg Infect Dis.* 2004;10(1): 76-81.
- 23. Sib E, Lenz-Plet F, Barabasch V, et al. Bacteria isolated from hospital, municipal and slaughterhouse wastewaters show characteristic, different resistance profiles. *Sci Total Environ*. 2020;746:140894.
- Dalton KR, Rock C, Carroll KC, Davis MF. One health in hospitals: how understanding the dynamics of people, animals, and the hospital built-environment can be used to better inform interventions for antimicrobial-resistant gram-positive infections. *Antimicrob Resist Infect Control*. 2020;9(1):78.